Absci Corporation (ABSI)
Market Cap | 640.62M |
Revenue (ttm) | 5.72M |
Net Income (ttm) | -110.57M |
Shares Out | 112.79M |
EPS (ttm) | -1.20 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,207,791 |
Open | 5.54 |
Previous Close | 5.54 |
Day's Range | 5.51 - 5.76 |
52-Week Range | 1.11 - 6.40 |
Beta | 2.36 |
Analysts | Strong Buy |
Price Target | 10.20 (+79.58%) |
Earnings Date | Nov 8, 2022 |
About ABSI
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington. [Read more]
Financial Performance
In 2023, Absci's revenue was $5.72 million, a decrease of -0.50% compared to the previous year's $5.75 million. Losses were -$110.57 million, 5.40% more than in 2022.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ABSI stock is "Strong Buy." The 12-month stock price forecast is $10.2, which is an increase of 79.58% from the latest price.
News
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance ...
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten publi...
Absci Announces Pricing of Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the pricing of an underwritten public ...
Absci Announces Proposed Public Offering of Common Stock
VANCOUVER, Wash., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, announced today that it has commenced an underwritten ...
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
VANCOUVER, Wash., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” ...
Absci to Participate in the 26th Annual Needham Growth Conference
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in...
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten new Act...
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
Collaboration Combines Absci's AI Antibody Drug Creation Platform with AstraZeneca's Expertise in Oncology Research and Development Collaboration Combines Absci's AI Antibody Drug Creation Platform wi...
AstraZeneca, AI biologics firm Absci tie up on cancer drug - FT
Anglo-Swedish drugmaker AstraZeneca has signed a deal worth up to $247 million with U.S. artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times re...
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
BARCELONA, Spain & VANCOUVER, Wash.--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI...
Absci to Participate in Upcoming Investor Conferences
VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the follo...
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural R&D Day ...
Absci to Host R&D Day on October 4, 2023
VANCOUVER, Wash. and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will host its first R&D Day on We...
Biotech company Absci lays off 30 employees, about 15% of staff
Publicly traded biotech company Absci is laying off 30 employees, or approximately 15% of its workforce.
Absci Reports Business Updates and Second Quarter 2023 Financial and Operating Results
Entered into partnership with Google Ventures-backed biotech company to discover innovative new medicines Entered into collaboration with Caltech, supported by the Gates Foundation, to discover afford...
Absci Appoints Zach Jonasson, Ph.D., as Chief Financial Officer and Chief Business Officer
Addition of veteran biotech leader to further support Absci's next stage of growth Addition of veteran biotech leader to further support Absci's next stage of growth
Absci and Caltech Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development
VANCOUVER, Wash., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced that leading researchers at the California Institute of Te...
Absci to Participate in the UBS MedTech, Tools and Genomics Summit 2023
VANCOUVER, Wash. and NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci to Participate in the Morgan Stanley 2nd Annual Biotechnology AI Summit
VANCOUVER, Wash. and NEW YORK, June 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcom...
Absci Evolves its Board of Directors with HealthTech Luminary Frans van Houten, Former CEO of Philips
VANCOUVER, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a generative AI drug creation company, today announced the appointment of Frans van Houten to its Board of Directors. With his...
Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results
Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate